BioCryst to Present at Upcoming Investor Conferences
06 May 2022 - 9:00PM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
that the company will present at the following conferences:
- The Bank of America Securities 2022
Healthcare Conference in Las Vegas, NV on Tuesday, May 10, 2022, at
11:00 a.m. ET.
- The RBC Capital Markets Global
Healthcare Conference in New York on Wednesday, May 18, 2022 at
1:35 p.m. ET.
- The H.C. Wainwright Global
Investment Conference – pre-recorded fireside chat available
beginning Tuesday, May 24, 2022 at 7:00 a.m. ET.
Links to a live audio webcast and replay of
these presentations may be accessed in the Investors & Media
section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. Oral, once-daily ORLADEYO®
(berotralstat) is approved in the United States, the European
Union, Japan, the United Kingdom and the United Arab Emirates.
BioCryst has several ongoing development programs including
BCX9930, an oral Factor D inhibitor for the treatment of
complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva, and
galidesivir, a potential treatment for Marburg virus disease and
Yellow Fever. RAPIVAB® (peramivir injection) has received
regulatory approval in the U.S., Canada, Australia, Japan, Taiwan
and Korea. Post-marketing commitments for RAPIVAB are ongoing. For
more information, please visit the company’s website
at www.biocryst.com.
BCRXW
Investor Contact:John Bluth+1
919 859 7910jbluth@biocryst.com
Media Contact:Catherine
Collier Kyroulis+1 917 886 5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to May 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From May 2023 to May 2024
